Edmund Tsui, MD

Edmund Tsui, MD, MS

Associate Professor, Department of Ophthalmology

Languages

English

Education

Fellowship

Uveitis, Medical Cornea, and Ocular Inflammatory Diseases, Francis I. Proctor Foundation, University of California, San Francisco, CA, 2019

Internship

General Surgery, Dartmouth-Hitchcock Medical Center, 2015

Degrees

MS, David Geffen School of Medicine, University of California, Los Angeles, CA, 2023
MD, Geisel School of Medicine, Dartmouth, Hanover, NH, 2014
BS, The University of Western Ontario, London, Ontario, 2010

Residencies

General Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2015
Ophthalmology, New York University School of Medicine, New York, NY, 2018

Board Certification

Ophthalmology, American Board of Ophthalmology, 2019

Contact Information

Scientific Interests

Dr. Tsui's primary cancer-relevant research focuses on immune-related adverse events associated with  cancer therapeutics, with particular emphasis on ocular toxicities. His work centers on uveitis and other ocular complications arising from medications such as immune checkpoint inhibitors and antibody drug conjugates, with the goal of identifying predictors of toxicity. Dr. Tsui's research integrates rigorous  clinical phenotyping and multidisciplinary collaboration to improve early detection, risk stratification, and management of therapy-related ocular inflammation while preserving visual function.

Highlighted Publications

Chew L, Feng J, Hutchins E, Stein-Merlob AF, Yang EH, Lechner MG, Tsui E. Immune Checkpoint Inhibitor-Associated Uveitis: Predictors and Survival Impact. Ophthalmol Retina. 2026 Feb;10(2):215-217. doi: 10.1016/j.oret.2025.11.001. Epub 2025 Nov 11. PMID: 41232602.

Haidar AJ, Chen A, Chen JL, Al-Hashimi S, Ghaffari RS, Fung S, Silverstein J, Konecny GE, Tsui E. Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy. JAMA Oncol. 2026 Jan 2:e255763. doi: 10.1001/jamaoncol.2025.5763. Epub ahead of print. PMID: 41481303; PMCID: PMC12761749.

Chang EL, Liu R, Keyhanian K, Huynh K, Berkenstock M, Bhatti MT, Chen JJ, Chodosh J, Costello F, Dalvin LA, DeLott LB, Dinkin M, Egan RA, Fraser CL, Freitag SK, Gangaputra S, Gordon LK, Guidon AC, Johnson DB, Kombo N, Kramer M, Lee AG, Levy M, Lobo-Chan AM, Mantopoulos D, Papaliodis G, Pless M, Pimkina J, Rubin KM, Sen HN, Shariff A, Subramanian PS, Tsui E, Yoon MK, McDunn J, Rine J, Reynolds KL, Sobrin L, Chwalisz BK. Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2025 Apr 8;13(4):e011049. PMID: 40199607; PMCID: PMC11979595.

Louie MS, Brice NA, Tsui E, Chen JL, McCannel CA. Report of a case of nasaltype extranodal NK/T-cell lymphoma with ciliary body involvement and literature review of interleukin-10 and interleukin-6 in intraocular T-cell lymphoma. Am J Ophthalmol Case Rep. 2025 Nov 18;40:102483. doi: 10.1016/j.ajoc.2025.102483. PMID: 41377857; PMCID: PMC12686643.

Feo A, Popovic MM, Tsui E. Angular Sign of Henle Fiber Layer Hyperreflectivity (ASHH) in Cancer-Associated Retinopathy. Ocul Immunol Inflamm. 2025 Sep 12:1-5. doi: 10.1080/09273948.2025.2552925. Epub ahead of print. PMID: 40939111.